Introduction:

The use of biological therapy has been associated with an increased risk for different types of infections. In this sense, the development of strategies for prevention and treatment of infections in patients with rheumatic diseases with biological therapy is essential. Currently there is little information on the seroprevalence of Chagas disease (CD) and toxoplasmosis in patients with rheumatic diseases.

Objective:

To analyze the seroprevalence of CD and toxoplasmosis in patients with rheumatic diseases in plans to start BT.

Methodology:

Retrospective study of patients with rheumatic diseases whit criteria to start a BT in the Rheumatology Service of the IPS Central Hospital. Clinical, epidemiological, serological and treatment-related variables were recorded. The frequency of positive serology for CD and toxoplasmosis was analyzed and the association with the collected variables was studied.

Results:

228 patients were included (RA = 176, Sp = 43, Collagenopathy = 9), 74.6% were women with a mean age of 46.2 years. Chagas seroprevalence was 2.9% and toxoplasmosis 63.1%. No significant associations were identified with the analyzed variables.

Conclusion:

The seroprevalence of toxoplasmosis and Chagas disease was similar to that described in studies of the general population of our country and the region, so it is important to always keep them in mind especially in developing countries.1Q In the present study, a reactivation of the disease after the onset of BT was not found.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )